| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study
|
Stacchiotti, S.
|
|
2019
|
106 |
C |
p. 225-233
|
artikel
|
| 2 |
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
|
Dimopoulos, Meletios A.
|
|
2019
|
106 |
C |
p. 89-98
|
artikel
|
| 3 |
Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis
|
Mackay, Tara M.
|
|
2019
|
106 |
C |
p. 99-105
|
artikel
|
| 4 |
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA
|
Ye, Zhong
|
|
2019
|
106 |
C |
p. 133-143
|
artikel
|
| 5 |
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
|
Haslam, Alyson
|
|
2019
|
106 |
C |
p. 196-211
|
artikel
|
| 6 |
Diet-dependent toxicity of ipilimumab in metastatic melanoma
|
Majenka, P.
|
|
2019
|
106 |
C |
p. 220-224
|
artikel
|
| 7 |
Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score–matched analysis
|
Imanishi, Mamiko
|
|
2019
|
106 |
C |
p. 69-77
|
artikel
|
| 8 |
Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
|
Baraniskin, Alexander
|
|
2019
|
106 |
C |
p. 37-44
|
artikel
|
| 9 |
European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer
|
Rutgers, Emiel
|
|
2019
|
106 |
C |
p. 45-53
|
artikel
|
| 10 |
Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials
|
Nie, Run-Cong
|
|
2019
|
106 |
C |
p. 1-11
|
artikel
|
| 11 |
Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors
|
de Malet, Alice
|
|
2019
|
106 |
C |
p. 106-114
|
artikel
|
| 12 |
Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations
|
Singer, Christian F.
|
|
2019
|
106 |
C |
p. 54-60
|
artikel
|
| 13 |
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT
|
Giebel, Sebastian
|
|
2019
|
106 |
C |
p. 212-219
|
artikel
|
| 14 |
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer
|
Tahara, Makoto
|
|
2019
|
106 |
C |
p. 61-68
|
artikel
|
| 15 |
Induction chemotherapy in borderline (non-)resectable pancreatic cancer: a unique window of opportunity for understanding pancreatic cancer
|
Van Laethem, Jean-Luc
|
|
2019
|
106 |
C |
p. 34-36
|
artikel
|
| 16 |
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial
|
Schneeweiss, Andreas
|
|
2019
|
106 |
C |
p. 181-192
|
artikel
|
| 17 |
Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study
|
Effinger, Karen E.
|
|
2019
|
106 |
C |
p. 171-180
|
artikel
|
| 18 |
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments
|
Tavolari, S.
|
|
2019
|
106 |
C |
p. 160-170
|
artikel
|
| 19 |
Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) report
|
Aronson, Daniel C.
|
|
2019
|
106 |
C |
p. 126-132
|
artikel
|
| 20 |
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
|
Moreira, Alvaro
|
|
2019
|
106 |
C |
p. 12-23
|
artikel
|
| 21 |
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
|
Eckstein, Markus
|
|
2019
|
106 |
C |
p. 234-243
|
artikel
|
| 22 |
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
|
Prelaj, Arsela
|
|
2019
|
106 |
C |
p. 144-159
|
artikel
|
| 23 |
Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti–programmed death 1 antibody
|
Shirai, T.
|
|
2019
|
106 |
C |
p. 193-195
|
artikel
|
| 24 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Hubner, Richard A.
|
|
2019
|
106 |
C |
p. 24-33
|
artikel
|
| 25 |
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
|
Holch, J.W.
|
|
2019
|
106 |
C |
p. 115-125
|
artikel
|
| 26 |
Reviewers 2018
|
|
|
2019
|
106 |
C |
p. 244
|
artikel
|
| 27 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)
|
Ioka, Tatsuya
|
|
2019
|
106 |
C |
p. 78-88
|
artikel
|
Tijdschrift beschrijving